January 13, 2025 – Talk Bio

Eli Lilly Acquires Scorpion Therapeutics for Up to $2.5 Billion to Bolster Oncology Pipeline

3 months ago talkbio0Tagged Acquisition, Cancer Therapeutic Procedure, Eli, Eli Lilly, Inhibitor, Oncology Pipeline, PI3Kδ, Scorpions, STX-478

Eli Lilly, Scorpion Therapeutics, PI3Kα inhibitor, STX-478, cancer treatment, oncology pipeline, acquisition, biotech deal

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

3 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

3 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder

GSK Initiates JPM Deal-making with $1 Billion Acquisition of IDRx for Rare Cancer Treatment

3 months ago talkbio0Tagged Acquisition, IDRx, JPM, Malignant Neoplasms, SmithKline Beecham

GSK, IDRx, JPM, rare cancer, acquisition, biotech, pharmaceuticals

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

3 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

Eli Lilly Acquires Scorpion Therapeutics in $2.5 Billion Deal to Boost Breast Cancer Treatment Options

3 months ago talkbio0Tagged Eli, Eli Lilly, Inhibitor, Malignant neoplasm of breast, Oncology Pipeline, PI3Kδ, Scorpions, STX-478

Eli Lilly, Scorpion Therapeutics, breast cancer, PI3Kα inhibitor, STX-478, oncology pipeline, targeted therapy

Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma

3 months ago talkbio0Tagged Asthma, COPD, Eczema, Gilead Sciences, Inflammatory disorder, inhibitors, JPM25, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25

Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Depressive disorder, Neurology speciality, zuranolone

Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder

Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

3 months ago talkbio0Tagged Dermatology field, Gilead Sciences, Inflammatory disorder, oral formulations, Partnership, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology

Regor’s Obesity Pill RGT-075 Shows Moderate Weight Loss in Phase 2a, Advances to Phase 2b Trial

3 months ago talkbio0Tagged GLP-1 receptor, Obesity, Oral Medication, phase 2a, Phase 2b Trial, RGT-075

RGT-075, obesity treatment, GLP-1 receptor agonist, oral medication, Phase 2a results, Phase 2b trial